Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | GB226 |
Indication/Tumor Type | alveolar soft part sarcoma |
Response Type | not predictive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | alveolar soft part sarcoma | not predictive | GB226 | Phase II | Actionable | In a Phase II trial (Gxplore-005), patients with CD274 (PD-L1)-positive (CPS >=1%) alveolar soft part sarcoma achieved an objective response rate (ORR) of 33.3% (4/12; 95% CI 9.9-65.1) and a disease control rate (DCR) of 83.3% (10/12; 95% CI 51.6-97.9) in response to Geptanolimab (GB226) treatment, which were not different from the 40.0% ORR (10/25; 95% CI 21.1-61.3) and 88.0% DCR (22/25; 95% CI 68.8-97.5) observed in CD274 (PD-L1)-negative (CPS <1%) patients (PMID: 33046518; NCT03623581). | 33046518 |
PubMed Id | Reference Title | Details |
---|---|---|
(33046518) | Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. | Full reference... |